SCHEMBL3424022

SCHEMBL3424022

COc1cccn(-c2c(C)cc([N+](=O)[O-])cc2C)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
MAPT P10636 5/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
HTT P42858 2/20 0.40
TDP1 Q9NUW8 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.38
MAPK1 P28482 2/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
CYP3A4 P08684 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
POLB P06746 2/20 0.37
PKM P14618 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
RECQL P46063 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27909201 0.85 RECQL (0.45) ALDH1A1MAPTMEN1KMT2AHTT
SCHEMBL3419872 0.84 MAPT (0.47) ALDH1A1MAPTMEN1KMT2AHTT
SCHEMBL3678417 0.81 F2RL3 (0.36) ALDH1A1MAPTMEN1KMT2AHTT
SCHEMBL2473570 0.81 ALDH1A1 (0.41) ALDH1A1MEN1KMT2ATDP1MAPK1
SCHEMBL3644238 0.81 ALDH1A1 (0.43) ALDH1A1MAPTMEN1KMT2AHTT
SCHEMBL3419901 0.80 NQO2 (0.40) ALDH1A1MAPTMEN1KMT2ATDP1
SCHEMBL2477291 0.77 ALDH1A1 (0.39) ALDH1A1MAPTMEN1KMT2ATDP1
SCHEMBL2471712 0.76 RAB9A (0.38) ALDH1A1MAPTMEN1KMT2AHTT
SCHEMBL3639740 0.75 MAPT (0.61) ALDH1A1MAPTMEN1KMT2AHTT
SCHEMBL15929085 0.74 MAPT (0.36) ALDH1A1MAPTMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846934-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-30 US disclosed
US-8846934-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-30 US disclosed
US-8846934-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-30 US disclosed
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-27 US disclosed
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-27 US disclosed
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-27 US disclosed
US-8383822-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-26 US disclosed
US-8383822-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-26 US disclosed
US-8383822-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-26 US disclosed
EP-2170877-B1 SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION BAYER IP GMBH (DE) 2012-11-21 EP disclosed
EP-2167499-B1 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF Bayer Pharma AG (DE) 2011-12-14 EP disclosed
EP-2167499-B1 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF Bayer Pharma AG (DE) 2011-12-14 EP disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-07-22 US disclosed
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-07-22 US disclosed
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-07-22 US disclosed
EP-2167499-A2 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF Bayer Schering Pharma AG (DE) 2010-03-31 EP disclosed
WO-2008155069-A2 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, OXA1L, PPOX ALDH1A1 441/4885MAPT 4810/4885MEN1 1934/4885
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, MPL, OXA1L ALDH1A1 523/4885MAPT 4772/4885MEN1 1705/4885
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, MPL, OXA1L ALDH1A1 523/4885MAPT 4772/4885MEN1 1705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.